Working together on an integrated digital platform for cell and gene therapy developers

The com­pa­nies ATMPS Ltd and Ori Biotech announced a glob­al col­lab­o­ra­tion to cre­ate seam­less inte­gra­tion between their respec­tive data plat­forms to sup­port the devel­op­ment of Advanced Ther­a­pies. The non-exclu­sive part­ner­ship will result in the inte­gra­tion of Ori’s pro­pri­etary CGT man­u­fac­tur­ing platform’s data archi­tec­ture with ATMPS’ Hataali^TM, a secure data shar­ing plat­form, spe­cial­ly designed as a scal­able sys­tem for advanced ther­a­pies. The com­bi­na­tion of the two pro­pri­etary plat­forms will pro­vide improved prod­uct track­ing, sched­ul­ing as well as live mon­i­tor­ing of the man­u­fac­tur­ing sta­tus across the entire CGT sup­ply chain from vein to vein.
 

“Ori select­ed ATMPS’ Hataali tech­nol­o­gy for inte­gra­tion with our plat­form to allow the secure shar­ing of rel­e­vant process data with ther­a­py devel­op­ers, con­tract devel­op­ment and man­u­fac­tur­ing orga­ni­za­tions (CDMOs) and even clin­i­cians or patients in real-time. This col­lab­o­ra­tion will pro­vide increased vis­i­bil­i­ty into the treat­ment process for those involved at each stage of the treat­ment process, The addi­tion of estab­lished tech­nolo­gies from com­pa­nies like ATMPS allows Ori to fur­ther its mis­sion of enabling part­ners across the CGT indus­try to bring ther­a­pies as safe­ly, cost effec­tive­ly and quick­ly as pos­si­ble to large num­bers of patients with few alter­na­tive ther­a­peu­tic options.”
— Jason C. Fos­ter, CEO, Ori Biotech

 
Hataali encrypts and stores data using dis­trib­uted ledger tech­nol­o­gy through a process known as hash­ing. This process ensures data secu­ri­ty is pro­tect­ed through a sys­tem of pri­vate keys and cryp­tog­ra­phy. Hataali was the first cell orches­tra­tion plat­form installed in a hos­pi­tal glob­al­ly and ATMPS the first blockchain com­pa­ny to inte­grate with the UK Nation­al Health Ser­vice for the deliv­ery of advanced therapies.
“Ori is an ide­al part­ner for ATMPS, as both com­pa­nies share a com­mon mis­sion to low­er the costs and improve process­es for cell and gene ther­a­pies. Ori’s work in help­ing inno­va­tors scale from pre­clin­i­cal to com­mer­cial is a mas­sive step towards reduc­ing com­plex­i­ty and bring­ing these vital ther­a­pies to patients more quick­ly,” said Raja Sharif, CEO, ATMPS. “We all know how chal­leng­ing and expen­sive the devel­op­ment and man­u­fac­tur­ing of CGTs can be. With the help of Hataali, Ori can secure­ly lever­age vein-to-vein data to advance their man­u­fac­tur­ing solu­tions much more effi­cient­ly. This will enable real-time ther­a­py track­ing, improved patient trust and expe­di­at­ed clin­i­cal development.”